1Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China;
2Department of Gastroenterology, Chinese PLA General Hospital, Beijing 100853, China
ZHANG Ru, LV Hong, QIAN Jia-ming, SHEN Bing-bing, YANG Xiao-ou, CHEN Qiang. The Significance of Clinical Features of Crohn's Disease in Treatment Modalities[J]. Chinese Journal of Pharmacovigilance, 2010, 7(5): 269-271.
[1] Travis SPL, Stange E F, Lémann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management[J]. Gut, 2006,55:i16-i35.
[2] Gupta N, Cohen S A, Bostrom A G, et al. Risk factors for initial surgery in pediatric patients with Crohn's disease[J]. Gastroenterology, 2006 ,Apr130(4):1069-1077.
[3] Forcione D G, Rosen M J, Kisiel J B, et al. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease[J]. Gut,2004, Aug53(8):1117-1122.
[4] Esters N, Vermeire S, Joossens S, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease[J]. Am J Gastroenterol,2002 ,Jun97(6):1458-1462.